<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03385551</url>
  </required_header>
  <id_info>
    <org_study_id>IP-AVV2017</org_study_id>
    <nct_id>NCT03385551</nct_id>
  </id_info>
  <brief_title>Evaluation of the Acceptability and Efficacy of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream</brief_title>
  <official_title>Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the acceptability, efficacy and preferences of 10 of estradiol
      vaginal tablets vs promestriene vaginal cream
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, prospective, multicenter, open-label, randomized, parallel-group
      study to evaluate the acceptability, efficacy and preferences of postmenopausal women older
      than 45 between 10 micrograms of estradiol vaginal tablets vs promestriene vaginal cream
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vulvovaginal Symptoms</measure>
    <time_frame>Change from Baseline, at week 4 and at week 12</time_frame>
    <description>Dispareunya, dryness, itching nd burning</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Vulvovaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 micrograms of estradiol vaginal tablets. One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments to maintain therapeutic response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Promestriene 10 mlligrams / grams vaginal cream. 1 gr. One application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments to maintain therapeutic response</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>Estradiol or Promestriene depending on the arm</description>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_label>ARM 2</arm_group_label>
    <other_name>Promestriene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women aged 45 years or older. Women will be considered postmenopausal
             with more than 12 months since last menstrual period

               -  Women with an intact uterus

               -  One or more vaginal symptoms (dryness, soreness, irritation, dyspareunia) rated
                  as moderate to severe. Symptoms are moderate if the patient needs a treatment and
                  feels discomfort. Symptoms are severe if the patient needs a treatment, and feels
                  such a degree of discomfort that this could severely impact the subject's daily
                  activities.

               -  . In case of doubt, blood estradiol concentration will be determined, and the
                  subject will only be enrolled if the levels are equal to 30pg./ml. or less.

        Exclusion Criteria:

          -  Women who had a known or suspected history of breast carcinoma

               -  Estrogen dependent neoplasia. Women with a known, past or suscpected
                  Estrogen-dependent malignant tumours such as endormetrial or ovarian cancer

               -  Positive or suspicious mammogram results

               -  Any systemic malignant disease

               -  Hormone therapy treatment (sex hormones or vaginal treatments or steroids) in the
                  last three months Women who had abnormal vaginal bleeding or uterine bleeding of
                  unknown cause

               -  Vaginal infection requiring treatment

               -  Previous or current venous thromboembolism (deep venous thrombosis, pulmonary
                  embolism) Untreated endometrial hyperplasia Known thrombophilic disorders (e.g.
                  protein C, protein S, or antithrombin deficiency) Active or previous arterial
                  thromboembolic disease (e.g. angina, myocardial infarction) Acute liver disease,
                  or history of liver disease as long as liver function tests have failed to return
                  to normal Known Hypersensitivity to the active substances or to any of the
                  excipients Porphyria

               -  Any serious disease or chronic condition that could interfere with study
                  compliance

               -  History of thrombolytic disorders

               -  Use of vaginal contraceptives (DIU, vaginal ringâ€¦)

               -  Participation in another clinical trial in the last three months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal Women</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Palacios, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Palacios</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Santiago Palacios, MD</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>investigacion@institutopalacios.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Soler, SC</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>eva.maria.soler@institutopalacios.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS &quot;S Matteo Foundation&quot;</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosella Nappi, MD</last_name>
      <email>renappi@tin.it</email>
    </contact>
    <contact_backup>
      <last_name>Rosella Nappi</last_name>
      <email>renappi@tin.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Santiago Palacios, MD</last_name>
      <phone>915780517</phone>
      <email>investigacion@institutopalacios.com</email>
    </contact>
    <contact_backup>
      <last_name>Eva Soler</last_name>
      <phone>915780517</phone>
      <email>eva.maria.soler@institutopalacios.com</email>
    </contact_backup>
    <investigator>
      <last_name>Santiago Palacios, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vulvovaginal Atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

